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Abstract: The diurnal rhythm of bone remodeling suggests nocturnal dietary intervention to be most
effective. This study investigated the effect of bedtime ingestion of a calcium-fortified, milk-derived
protein matrix (MBPM) or maltodextrin (CON) on acute (0–4 h) blood and 24-h urinary change in
biomarkers of bone remodeling in postmenopausal women with osteopenia. In CON, participants
received 804 ± 52 mg calcium, 8.2 ± 3.2 µg vitamin D and 1.3 ± 0.2 g/kg BM protein per day. MBPM
increased calcium intake to 1679 ± 196 mg, vitamin D to 9.2 ± 3.1 µg and protein to 1.6 ± 0.2 g/kg
BM. Serum C-terminal cross-linked telopeptide of type I collagen (CTX) and procollagen type 1
amino-terminal propeptide (P1NP), and urinary N-telopeptide cross-links of type I collagen (NTX),
pyridinoline (PYD) and deoxypyridinoline (DPD) was measured. Analyzed by AUC and compared
to CON, a −32% lower CTX (p = 0.011, d = 0.83) and 24% (p = 0.52, d = 0.2) increase in P1NP was
observed for MBPM. Mean total 24 h NTX excreted in MBPM was −10% (p = 0.035) lower than CON.
Urinary PYD and DPD were unaffected by treatment. This study demonstrates the acute effects of
bedtime ingestion of a calcium-fortified, milk-based protein matrix on bone remodeling.
Keywords: randomized control trial; milk protein matrix; nutrient intervention; nutrient timing;
bone remodeling; bone turnover markers; bone health; osteopenia; postmenopausal women
1. Introduction
Low bone mineral density (bone mineral content) and a diminution in bone quality (bone
microarchitecture) are attributes of risk of fracture in people with osteopenia [1]. Bone architecture
and mineral content remodel continuously throughout life with high rate of bone tissue remodeling
an independent factor of fracture risk [2]. In the treatment of people with osteopenia, measurement
of change in remodeling rate through intervention informs clinical practice [3]. Diet is a modifiable,
lifestyle factor that can affect bone health and the risk of fracture. Therefore, a nutritional intervention
that positively modulates the linked remodeling processes of bone resorption and formation is an
attractive option in the maintenance of bone health.
Bone turnover markers (BTM) of bone resorption (C-terminal cross-linked telopeptide of type
I collagen, CTX) and formation (total procollagen type 1 amino-terminal propeptide, P1NP) inform
of change in bone metabolism and bone health earlier, and with greater sensitivity than change in
bone mineral density (BMD) [4]. Defined by circadian variation in BTM, bone remodeling exhibits a
unimodal diurnal rhythm with a nocturnal peak and daytime nadir [5–8]. The diurnal amplitude of
bone resorption is greater than of the bone formation and is, thereby, considered the more prominent and
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sensitive biomarker of change in bone remodeling. The ratio of biomarkers of bone formation/resorption
(i.e., P1NP/CTX ratio) tracks the temporal balance of bone remodeling throughout the day [5].
Bone remodeling is sensitive to modulation by feeding and nutrient specific intake. The response
of bone remodeling to food ingestion is linked putatively to the secretion of enterogastric hormones
glucose-dependent insulinotropic peptide (GIP1–42) and glucagon-like peptide-1 (GLP-17–36) acting
via an entero-osseous axis [9]. The antiresorptive effect of a postprandial rise in GIP and GLP-1
acts to decrease osteoclast activity [10] resulting in a ~20% decrease in CTX in healthy adults [11,12].
Specific nutrient intake includes calcium and vitamin D, key nutrients for bone health [13]. Intake
of calcium and vitamin D suppress parathyroid activity leading to decreased parathyroid hormone
(PTH) secretion and reduction in bone resorption activity [14]. Dietary and/or supplemental intake
of these nutrients is advised by reference to population-based recommended intake per diem. Few
nutritional studies of bone metabolism time supplemental intervention to act at the nocturnal peak of
bone remodeling [15].
The matrix of nutrients within dairy-based food products are potent comodulators of bone
remodeling [16]. Superior to an individual nutrient, a food matrix contains multiple nutrients of
individual biofunctionality that are pluripotent in effect when consumed as a whole [17]. Timed to act
during the nocturnal peak rate of bone remodeling, we report the outcome of a randomized control
trial investigating the effect of feeding a milk protein-based matrix (MBPM) fortified with calcium and
vitamin D prior to bedtime on the acute (0–4 h) and 24 h change in biomarkers of bone remodeling in
postmenopausal women with osteopenia. An isoenergetic maltodextrin acted as a control (CON).
2. Materials and Methods
The study was approved by the University of Limerick, Faculty of Education and Health Sciences
Research Ethics Committee (2017_06_03_EHS). Participants were informed of the purpose of the
study and all known risks before providing written, informed consent. The study was conducted in
accordance with the ethical standards outlined in the most recent version of the Declaration of Helsinki
and registered with clinicaltrials.gov identifier NCT03337971.
2.1. Participant Recruitment and Progression
A convenience sample of 41 postmenopausal women aged 50 to 70 y recruited from the University
of Limerick Body Composition (ULBC) Study database by invitation. ULBC subjects had preassigned
alphanumeric ID codes that continued to the present study. Subject volunteers were free-living,
lactose tolerant, and devoid of treatment for osteoporosis or drugs affecting calcium absorption. Dual
energy X-ray absorptiometric (DXA; Lunar iDXA™with enCORE™ 2007 v.17 software, GE Healthcare,
Chalfont St Giles, Bucks., UK) measurement of AP spine (L1–L4) and dual femur BMD (femoral neck),
conducted and analyzed in accordance with the International Society for Clinical Densitometry [18],
confirmed eligibility (BMD T scores < −1.0, ≥ −2.5). Twenty-four volunteers confirmed as osteopenic
submitted to a clinical examination, blood screen and 7-day weighed food dietary intake record.
Following screening five volunteers declined to participate further and two excluded based on
medication (treatment for osteoporosis: n = 1; medication with Gabapentin™: n = 1). One participant
was unable to attend during the intervention periodThe remaining 16 volunteers progressed to the RCT
and randomly assigned to receive either a milk-based protein supplement (MBPM) or an isoenergetic,
maltodextrin control (CON) over two consecutive days (Figure 1). Supplementary Figure S1 provides
a CONSORT flowchart and checklist for this randomized trial.
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meal preparation. Subsequent coding and analysis was completed using Nutritics™ Dietary Analysis 
Software (Nutritics© software version 4.0 for Ireland). Dietary intake was compared to reference 
intakes (DRIs) developed by the Food and Nutrition Board (FNB) at the Institute of Medicine (IOM) 
of The National Academies [19]. 
Based on the 7-day dietary intake data a 48 h dietary standardization, representative of the 
individual’s reported habitual dietary patterns of the research population, compliant with dietary 
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preferences and normalized to body mass was prescribed for each participant by a registered 
dietitian. Each participant received the same meal plan on each of day of the intervention. 
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received a supplemental intake of MBPM or CON. The nutrient composition of MBPM and CON 
(Supplementary Table S1) comprised an additional 0.3 g/kg body mass protein and 0.3 g/kg body 
mass carbohydrate in the MBPM and an equivalent amount of carbohydrate energy, i.e., 0.6 g/kg 
body mass the CON arm of the study. Supplementary Tables S2 and S3 report the prescribed dietary 
intakes inclusive of either MBPM or CON. 
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2.2. Study Design
A block-randomized, within-subject crossover design examining acute (0–4 h) and 24 h change in
biomarkers of bone turnover in healthy, postmenopausal women with osteopenia following ingestion
of MBPM or CON was conducted. Estimated from a least significant change in bone resorption (i.e., a
30% reduction in CTX with feeding) statistical power (1-β) of 80% and two-sided α of 0.05 would be
achieved by a sample size of 16 participants.
2.3. Dietary Intake and Standardized Diets for the Intervention
Following instruction from a qualified dietitian, participants recorded their dietary intake for
seven consecutive days (5 weekdays, 2 weekend days) using a weighed food and fluid log. Participants
reported food type, brand name, quantity, cooking method, type, time, and location of meal preparation.
Subsequent coding and analysis was completed using Nutritics™ Dietary Analysis Software (Nutritics©
software version 4.0 for Ireland). Dietary intake was compared to reference intakes (DRIs) developed by
the Food and Nutrition Board (FNB) at the Institute of Medicine (IOM) of The National Academies [19].
Based on the 7-day dietary intake data a 48 h dietary standardization, representative of the
individual’s reported habitual dietary patterns of the research population, compliant with dietary
recommendations (IOM DRIs) for energy, protein, and calcium, reflective of participants’ food
preferences and normalized to body mass was prescribed for each participant by a registered dietitian.
Each participant received the same meal plan on each of day of the intervention. Individuals’
standardized diet was supplemented with CON or MBPM. At bedtime, participants received a
supplemental intake of MBPM or CON. The nutrient composition of MBPM and CON (Supplementary
Table S1) comprised an additional 0.3 g/kg body mass protein and 0.3 g/kg body mass carbohydrate in
the MBPM and an equivalent amount of carbohydrate energy, i.e., 0.6 g/kg body mass the CON arm of
the study. Supplementary Tables S2 and S3 report the prescribed dietary intakes inclusive of either
MBPM or CON.
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2.4. Trial Protocol and Procedures
Participants were resident at the University of Limerick during the consecutive 2-day, 2-night trial
(Figure 2). Participants were free-living but remained with the confines of the university campus and
refrained from moderate to strenuous physical activity during their stay. Participants arrived at 17:00 h
and settled into the residence before emptying the bladder. This marked the 24 h urine collection
starting point for day 1 and the end sampling point 24 h later. Each participant received standardized
meals and the same meal options at the same time points over both days. At 20:00 h a research nurse
inserted a cannula into a superficial arm vein and a blood draw (5 mL) was taken. Each participant
consumed either MBPM or CON at 22:00 h and retired to bed. Serial blood draws (5 mL) each hour for
a further 4 h and the cannula removed.
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Serum and plasma were separated by centrifugation at 10,000× g at 4 ◦C for 5 min and frozen
at −80 ◦C until an lysis. Sixteen of the 192 blood samples drawn were hemolyzed and not analyzed.
This reduced the full analysis from 3 participants. Active plasma GLP-1(7-36) and total GIP (1-42)
wa measured using the MSD® etabolic assay kits (Meso Scale Discovery, Rockville, MD, USA)
b ed on sandwich ELISA and according to the manufacturer’s instructions. The inter-assay CVs
were 7.3 and 16.1 for active GLP-1 and total GIP, respectively. Plasma CTX a d serum P1NP b 2-site
immunometric assay using electrochemiluminesc nt detection (Roche Cob s e411, Roche Diagnostics,
UK). Plasma par thyroid hormon (PTH) easured using th human bone magnetic bead panel-1 kit
(c t3 HBNMAG-51k, Millipore Corp ration, Billerica, MA, USA) employing Luminex™ technology. The
interassay CV was 5.3% for CTX, 4.5% for P1NP and <10% for PTH. 24 h urine collection co menced
at 17:00 h on day 1, following full void, to 17:00 h of the 2nd day. An aliquot of urine was frozen at
−20 ◦C until batch analysis for urinary free pyridin line (fPYD) and deoxypyridinoline (fDPD) by
LC-MS/MS [20], urina y N-terminal telopeptide of Type I collagen (uNTX) by commercial immunoassay
and creat n e (Jaffé method, Roche COBAS® C501, Roche, Burgess Hill, UK). Urinary assays w re
ndertaken by the Bioanalytical Facility, Univ rs ty of E st Anglia, Norwich, UK.
2.5. Statistical Analysis
Shapiro–Wilk test was applied to check for normality of the data that are presented as the mean
± SD unless stated otherwise. Temporal change in serially sampled data was analyzed by repeated
measures ANOVA, the level of significance for post-hoc tests subject to Bonferroni correction. Difference
between mean change attributed to CON and MBPM was analyzed by paired t-test. Cohen’s effect size
was calculated using the standard formula (t-score/
√
n). Statistical significance was set at p ≤ 0.05.
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3. Results
3.1. Subject Characteristics
The baseline characteristics of the subject population are representative of postmenopausal women
age 55 to 70 y (Table 1). Subjects confirmed as osteopenic based on the BMD T-score of the L1-L4 region
of the spine.
Table 1. Subject population (n = 16).
Characteristic Unit Mean SD Range
Age y 64.7 3.3 55.8 to 69.5
Height cm 160.8 7.0 149.5 to 177.7
Weight kg 67.2 10.8 48.0 to 91.1
Body mass index kg·m−2 26.0 4.1 19.9 to 37.1
Fat mass kg 26.4 7.1 14.3 to 40.1
Lean mass kg 38.6 4.2 31.7 to 49.1
Body fat % 38.8 4.8 29.9 to 48.3
Dual Femur T-score −0.81 0.49 −1.5 to −0.05
BMDspine (L1–L4) T-score −1.65 0.47 −2.4 to −1.0
3.2. Dietary Intake
Reported mean daily intake, from a 7-day food and fluid log (Supplementary Table S4)
demonstrated adequacy of reported intakes among 81% of the study population for dietary protein
(1.13 ± 0.4 g/kg/d) when assessed relative to IOM RDA (0.8 g/kg/d). Forty-four percent reported mean
daily intakes of protein above 1.2 g/kg/d. The mean reported daily calcium intake (873 ± 366 mg)
surpassed the lowest acceptable intake (800 mg) for 50% of participants with only 25% of the population
reporting calcium intakes at or above the IOM RDA of 1200 mg. None of the study population met the
current IOM RDA for vitamin D (15 µg). Nine participants (56%) reported a mean daily vitamin D
intake below 5 µg per day.
Supplementary Table S4 provides individuals’ standardized nutrient intake for MBPM and
CON. MBPM and CON augmented individuals’ standardized total energy intake by 9% (to a mean
energy intake of approximately 2000 kcal). In addition, MBPM increased protein intake by 25%
(to 1.63 ± 0.19 g/kg/d), calcium by 109% (from 804 ± 153 to 1679 ± 196 mg) and vitamin D 12% (from
8.2 ± 3.2 to 9.2 ± 3.1 µg) (Table 2).
Table 2. Mean daily nutrient intake for the calcium-fortified, milk-derived protein matrix (MBPM) and
maltodextrin (CON) trials (n = 16).











Mean 2009 107.3 1.6 177.8 89.7 1679 9.2
SD 44 6.8 0.2 22.4 9.7 196 3.1
Min 1933 94.9 1.3 144.4 77.3 1345 3
Max 2079 120.3 2 217.2 107.7 2095 12.3
Mean Daily Intake in CON Trial
Mean 1994 85.2 1.3 203.7 89.7 804 8.2
SD 43 5.2 0.2 24 9.7 153 3.2
Min 1921 79.1 1 168.9 77.3 517 1.7
Max 2064 95.2 1.6 252.3 107.7 1013 11.2
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3.3. Enterogastric Response to Feeding
Feeding induced a differential response for GIP compared to GLP-1. The temporal change in GIP
was to increase by 40% from 109 ± 32 pmol/L to a peak of 152 ± 37 pmol/L 60 min postingestion in CON
and by 50% from 99± 30 pmol/L to a peak of 150± 39 pmol/L 60 min postingestion in MBPM. Thereafter,
GIP decreased to 60 ± 17 pmol/L residing 45% lower than prefeeding 4 h postingestion. Analyzed by
AUC, no difference in overall response between CON and MBPM was observed (Figure 3a).
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In contrast, GLP-1 decreased in a linear manner with time postfeeding in both trials. After 4h
GLP-1 decreased by 38% from 65 ± 16 pmol/L prefeeding to 40 ± 11 pmol/L after 4 h postingestion in
CON and by 30% from 72 ± 16 pmol/L to 51 ± 12 pmol/L 4 h postingestion in MBPM. No difference in
overall response between CON and MBPB was observed (Figure 3b).
3.4. Parathyroid Hormone and Bone Turnover Marker Response to Feeding
Feeding induced a differential PTH response for CON compared to MBPM. PTH increased by
15% from 3.53 ± 1.42 ng/mL to a peak of 4.0 ± 1.48 ng/mL 4 h postingestion in CON and decreased by
14% from 3.37 ± 1.44 ng/mL to a nadir of 2.9 ± 1.28 ng/mL 3 h postingestion in the MBPM arm of the
trial. Analyzed by AUC, a 2.3-fold lower response to MBPB than CON was observed (mean difference
−109 ng·min/mL; 95% CI −170, −48; p = 0.002, d = 1.08) (Figure 4a).
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Serum BTMs, CTX, and P1NP increased following feeding. The temporal change in CTX increased
by 43% from 0.32 ± 0.18 ng/mL to a peak of 0.45 ± 0.23 ng/mL 4 h postingestion in CON and by 21%
from 0.33 ± 18 ng/mL to peak at 0.43 ± 0.25 ng/mL 4 h postingestion in the MBPM arm of the trial.
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Analyzed by AUC, a −32% lower CTX response to MBPB than CON was observed (mean difference
−3.39 ± 4.0 ng·min/mL; 95%CI −5.84, 0.93; p = 0.011, d =0.83) (Figure 4b).
The temporal change in P1NP was a mean increase of 16% from 44.4 ± 19 ng/mL to peak at 51.3 ±
21 ng/mL 4 h postingestion in CON and by 19% from 40.8 ± 19 ng/mL to a peak of 48.3 ± 21 ng/mL 4
h postingestion in the MBPM arm of the trial. Analyzed by AUC, a 24% greater response to MBPB
than CON was observed (mean difference 116 ± 599 ng·min/mL; 95%CI −265, 497; p = 0.52, d = 0.2)
(Figure 4c).
3.5. Urinary 24 h BTM Excretion
Participants’ urine output varied from −750 to 1100 mL, resulting in a 4.1 ± 23% mean difference
in total 24-h urine volumes between days. However, total 24-h urinary creatinine excretion was not
significantly different between days (mean difference 0.0063 ± 0.17 g; 95%CI −0.085, 0.097; p = 0.89),
providing confidence that total urine collection was attained.
A large interindividual variation in 24 h urinary BTM excretion was observed (Figure 5). Mean
total 24 h NTX excreted for MBPM was −10 ± 16% lower than for CON (mean difference −43.2 ± 74.5
nmol BCE; 95%CI −82.9, 3.5, p = 0.035, d = 0.58), Figure 5a. No significant difference was observed in
mean 24 h excretion of PYD (219 ± 98 vs. 256 ± 107 nmol) or DPD (43.0 ± 24.6 vs. 47.3 ± 27.4 nmol) for
CON (Figure 5b) and MBPM (Figure 5c), respectively.
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4. Discussion
The reported baseline dietary intakes of the present cohort of Irish women with osteopenia were
comparable to results from the Irish National Adult Nutrition Survey (NANS) [21]. The mean total
energy (kcal) consumed per day by our population differed by only 6% to the mean energy intake in
the NANS study (1552 ± 382 kcal). The macronutrient contribution to total energy varied slightly in
our study (carbohydrate 40.4 ± 9.2%, protein 19.4 ± 6.4% and fat 36.3 ± 9.9%) vs. the NANS study
(carbohydrate 46 ± 5.9%, protein 18.3 ± 2.8%, and fat 35.5 ± 6.9%). The mean calcium content of the
baseline dietary record (876 ± 443 mg/day) exceeded the AR for calcium. However, these data are
distorted by the intake of calcium-containing dietary supplements, with only 56% (n = 9) of participants
actually achieving this by food intake alone. A difference of 11% was observed in dietary calcium
intake between our study sample and NANS data (MDI = 995 ± 573 mg/day) [10]. The habitual
dietary intake data confirmed adequacy of energy and essential nutrients and allowed an individual
Nutrients 2019, 11, 1413 8 of 11
standardized meal plan to be designed reflecting habitual intake over the 2-day study. The main
effect of the bed-time supplement was to increase mean daily, and specifically timed bed-time, energy,
protein, and calcium intake, by 9, 25, and 109%, respectively, in MBPM, and a matched energy intake
of 9% in CON. A nonhabitual bedtime supplemental mean intake of energy (166 kcal), protein (22.2 g),
and calcium (875 mg) was the nutrient intervention ascribed to MBPM.
The principal outcome of this block randomized, within subject crossover trial in postmenopausal
women with osteopenia was to effect a positive change in bone remodeling by nocturnal feeding.
Timed to coincide with peak rate of bone remodeling MBPM effected an acute (4 h) reduction in the
serum bone resorption marker CTX, a corresponding increase in the bone formation marker P1NP
and a moderately greater reduction in the P1NP/CTX ratio (mean difference −3.46; 95% CI −7.99, 1.07,
p = 0.12, d = 0.46) compared to CON. Though moderate in magnitude, the outcome of the nocturnal
feed was a transient reduction in the nocturnal peak of bone remodeling.
Ingestion of food increases enterogastric secretion of GIP and GLP-1 that are putative regulators
of bone metabolism acting on GIP and GLP-1 and 2 receptors located on bone resorbing osteoclasts
and bone forming osteoblasts [10–14]. CON and MPBP induced a similar enterogastric response.
GIP increased earlier, and to greater extent, than GLP-1 because GIP is secreted primarily from the
proximal duodenum, whereas GLP-1 is secreted from cells located primarily in the distal jejunum and
ileum. The lack of a differential response to secretion of incretins by MBPM over CON is surprising.
Milk-based protein increases the secretion of incretin hormones [22] and preserves incretin bioactivity
through the inhibition of dipeptidyl peptidase (DPP-IV) activity [23,24]. Furthermore, having similar
calcium content to MBPM (~850 mg) for co-ingestion with a mixed macronutrient meal has been
shown to augment the postprandial incretin response [25], in particular GIP (+47%), probably due
to the greater increase in calcium concentration in the duodenum than the ileum in the immediate
period postingestion.
The age-related increase in serum PTH levels with age is one attribute of age-related increase in
bone resorption. The secretion of PTH, a principal regulator of the quantity of remodeling activity,
responds to change in serum ionized calcium and is very much evident in the differential change
in circulating PTH between CON and MBPM. It follows that calcium intake induces a remodeling
transient and markers of bone metabolism react accordingly [26]. Though not timed specifically to
the nocturnal peak, provision of an oral calcium load of 0.2 g to late postmenopausal women with
normal calcium absorption significantly decreased serum CTX, for up to 5 h postingestion and can be
prolonged further by increasing the calcium load. [27]. Earlier studies designed to eliminate nocturnal
PTH transients by 24 h calcium infusion, or by anti-PTH antibodies, suggest that PTH may not mediate
the circadian pattern of bone resorption, but potentially influence the absolute rate of bone resorption
at which this pattern occurs [28]. Nutrition-induced nocturnal reduction in PTH would likely be
beneficial to an adaptive (reduced) rate of bone remodeling and preservation of bone health.
Exhibiting higher diurnal amplitude, the overall influence on circadian, 24-h bone resorption is
informed by the measurement of 24 h urinary N-telopeptide cross-links of type I collagen (NTX), and
associated cross-links pyridinoline (PYD) and deoxypyridinoline (DPD). A dilution of the acute (0–4 h),
transient change in BTM response to nocturnal feeding within a 24 h cycle was expected, but only 24 h
urinary NTX reflected the circulatory changes in BTM in the acute phase postfeeding. Furthermore, the
associated response of CTX (AUC0-240) and 24 h urinary NTX were significantly correlated (r = 0.71,
p < 0.001), whereas DPD (r = 0.022, p = 0.91) and PYD (r = 0.012, p = 0.9) were not. Earlier studies
demonstrate the value of urinary cross-links to monitor the circadian rhythm of bone resorption [6,29],
so the lack of treatment effect on the bone specific pyridinoline cross-links was surprising. Indeed, we
observed an almost 10-fold, intersubject 24 h excretion and high variability and sensitivity of response
to nocturnal feeding (Figure 5).
Protein constitutes ~50% of the volume of bone and approximately one-third of its mass. Therefore,
the turnover rate of Type I collagen is important to the maintenance of bone structure and bone
health. Similar to skeletal muscle, collagen turnover is a sensitive to nutritional modulation. Stable
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isotope studies of collagen synthesis report an increase in protein synthetic rate by ~66% following
intravenous nutrition (glucose, lipid emulsion, and amino acids in the ratio of 55%:30%:15% energy,
respectively) [30]. Controversy exists regarding recommendations for amount and type of dietary
protein for bone health [31]. Evidence in support of dairy protein intake is provided in a recent
review [32]. Equally, there is a strong link between calcium supplementation, particularly dairy-based
calcium, and bone health, especially in the elderly linked to the high bioavailability of calcium and
encrypted bioactive peptides/amino acids or proteins with the potential to improve calcium absorption
and regulate bone metabolism [33].
5. Conclusions
In summary, the reduction in AUC of CTX (−30% compared to CON) confirms our initial
hypothesis that a dairy-based protein supplement fortified with calcium (MBPM) fed at bedtime has a
potent effect on nocturnal rates of bone resorption in healthy osteopenic postmenopausal women. The
synergistic, pluripotent quality of a milk-based protein matrix and timing of ingestion to the nocturnal,
peak rate of bone remodeling transiently depressed bone turnover. We conclude that a late-evening
supplement of calcium-fortified milk protein affects a beneficial decrease in the homeostatic rate
of bone remodeling in persons at risk of degenerative bone disease. A 24-w longitudinal study
(clinicaltrials.gov identifier NCT03701113) is currently in progress to assess the efficacy of outcome in
bone turnover and BMD in this population.
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